Literature DB >> 12587826

Prevalence of T cell receptor zeta chain deficiency in systemic lupus erythematosus.

M P Nambiar1, J P Mitchell, R P Ceruti, M A Malloy, G C Tsokos.   

Abstract

T cells from patients with systemic lupus erythematosus (SLE) display antigen receptor-mediated signaling aberrations associated with defective T cell receptor (TCR) zeta chain expression. We determined the prevalence of TCR zeta chain deficiency in SLE from a large cohort of unselected racially diverse patients with different levels of clinical disease activity as determined by SLE Disease Activity Index (SLEDAI). Our data show that the occurrence of TCR zeta chain deficiency is 78% in SLE patients. There was no relationship between the deficiency of TCR zeta chain and the SLEDAI scores or theapy. TCR zeta chain deficiency was also not associated with age, race or gender and persisted over a 3 year follow-up period. Thus, there is a high prevalence of TCR zeta chain deficiency in SLE patients that is independent of disease activity, and persists over time indicating an important role for TCR zeta chain deficiency in SLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12587826     DOI: 10.1191/0961203303lu281oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

1.  [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Authors:  K W Frommer; M Geyer; G S Firestein
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

2.  Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

3.  CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3ζ-chain expression in T cells.

Authors:  Kyeong-Man Hong; Hyun-Kyoung Kim; Seong-Yeol Park; Shiv Poojan; Mi-Kyung Kim; Joohon Sung; Betty P Tsao; Jennifer M Grossman; Ornella J Rullo; Jennifer M P Woo; Deborah K McCurdy; Lisa G Rider; Frederick W Miller; Yeong-Wook Song
Journal:  Rheumatology (Oxford)       Date:  2017-03-01       Impact factor: 7.580

4.  Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription.

Authors:  Vaishali R Moulton; Alexandros P Grammatikos; Lisa M Fitzgerald; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

5.  Ubiquitination regulates expression of the serine/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells.

Authors:  Vaishali R Moulton; Andrew R Gillooly; George C Tsokos
Journal:  J Biol Chem       Date:  2013-12-24       Impact factor: 5.157

Review 6.  Novel molecular targets in the treatment of systemic lupus erythematosus.

Authors:  José C Crispín; George C Tsokos
Journal:  Autoimmun Rev       Date:  2007-12-04       Impact factor: 9.754

Review 7.  Systemic lupus erythematosus: new molecular targets.

Authors:  José C Crispín; Vasileios Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 8.  The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus.

Authors:  Gyorgy Nagy; Andras Perl
Journal:  Clin Immunol       Date:  2006-01-10       Impact factor: 3.969

Review 9.  The RNA binding protein SRSF1 is a master switch of gene expression and regulation in the immune system.

Authors:  Sean Paz; Anastasia Ritchie; Christopher Mauer; Massimo Caputi
Journal:  Cytokine Growth Factor Rev       Date:  2020-11-02       Impact factor: 7.638

Review 10.  Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.

Authors:  György Nagy; Agnes Koncz; Tiffany Telarico; David Fernandez; Barbara Ersek; Edit Buzás; András Perl
Journal:  Arthritis Res Ther       Date:  2010-06-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.